OSE Immunotherapeutics SA's latest marketcap:
As of 07/05/2025, OSE Immunotherapeutics SA's market capitalization has reached $137.86 M. According to our data, OSE Immunotherapeutics SA is the 22540th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 137.86 M |
| Revenue (ttm) | 98.24 M |
| Net Income (ttm) | 44.09 M |
| Shares Out | 22.87 M |
| EPS (ttm) | 1.72 |
| Forward PE | 5.66 |
| Ex-Dividend Date | n/a |
| Earnings Date | 06/26/2025 |
OSE Immunotherapeutics SA's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | €137.86 M | -27.02% | 22540 |
| 12/31/2024 | €156.83 M | 94.71% | 20267 |
| 12/29/2023 | €80.55 M | -34.73% | 23846 |
| 12/30/2022 | €123.4 M | -34.26% | 20523 |
| 12/31/2021 | €187.71 M | 45.49% | 18462 |
| 12/31/2020 | €129.02 M | 133.63% | 18030 |
| 12/31/2019 | €55.22 M | 9.99% | 20701 |
| 12/31/2018 | €50.21 M | -9.06% | 20213 |
| 12/29/2017 | €55.21 M | -45.3% | 20113 |
| 12/30/2016 | €100.94 M | 18.59% | 15678 |
Company Profile
About OSE Immunotherapeutics SA
OSE Immunotherapeutics SA is a clinical-stage biotechnology company specializing in immunotherapies for immune-oncology and immune-inflammation. Headquartered in Nantes, France, the company operates both domestically and internationally.
Key Products & Clinical Trials
- Tedopi – Phase III trial for non-small cell lung cancer; Phase II for pancreatic and ovarian cancer.
- OSE-279 – Phase I/II trial for advanced solid tumors or lymphomas.
- OSE-127 – Phase II trial for ulcerative colitis and Sjögren’s Syndrome.
- FR104 – Phase I trial for rheumatoid arthritis.
- BI 765063 – Phase I trial for solid tumors.
- OSE-230 – ChemR23 agonist antibody targeting chronic inflammation.
- CLEC-1 – Immune-oncology therapeutic target with monoclonal antibody antagonists.
- BiCKI – Bispecific checkpoint inhibitor platform targeting PD-1 to combat cancer resistance.
Collaborations & Partnerships
The company collaborates with leading institutions and pharmaceutical firms, including:
- GERCOR, ARCAGY-GINECO, Foundation FoRT, Nantes University Hospital
- Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, Chong Kun Dang Pharmaceutical Corporation
Company Background
Founded in 2012, OSE Immunotherapeutics SA was formerly known as OSE Pharma SA before rebranding in May 2016.
Frequently Asked Questions
-
What is OSE Immunotherapeutics SA's (EPA-OSE) current market cap?As of 07/05/2025, OSE Immunotherapeutics SA (including the parent company, if applicable) has an estimated market capitalization of $137.86 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does OSE Immunotherapeutics SA (EPA-OSE) rank globally by market cap?OSE Immunotherapeutics SA global market capitalization ranking is approximately 22540 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.